Actively Recruiting
A Real World Study About PMN
Led by Wei Chen · Updated on 2025-08-22
200
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous nephropathy. At the same time, the investigators conducted a real-world study on patients who did not meet the inclusion and exclusion criteria or were unwilling to enter the RCT cohort, to further observe the trial results in a broader population.
CONDITIONS
Official Title
A Real World Study About PMN
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with primary membranous nephropathy by kidney biopsy
- Aged over 18 years
- Average 24-hour urine protein of at least 3.5 grams twice a week after at least 3 months of ACE inhibitor or ARB treatment
You will not qualify if you...
- Secondary membranous nephropathy due to conditions like hepatitis B or C, lupus, cancer, or drug-related causes
- Active infections such as hepatitis B or C, tuberculosis within 1 year, or HIV infection
- History of immunodeficiency diseases or organ transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wei Chen
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
W
Wei Chen
CONTACT
Q
Qiong Wen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here